MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.mayocp.2013.11.019

Медицинская библиотека · Mayo Clinic proceedings · 2014

Cardiac and multiorgan transplantation for end-stage congenital heart disease.

Robinson Jeffrey A, Driscoll David J, O'Leary Patrick W, Burkhart Harold M, Dearani Joseph A, Daly Richard C, Edwards Brooks S, Dahl Sonja H, Johnson Jonathan N

СтатьяПеревод в очереди

Аннотация

OBJECTIVE

To report our single-center experience with patients who had cardiac and multiorgan transplantation for end-stage congenital heart disease (CHD).

PATIENTS AND

METHODS

We reviewed records for all patients with CHD who had undergone heart transplantation at Mayo Clinic, Rochester, Minnesota, from November 1, 1990, through June 30, 2012. Patients with cardiomyopathy were excluded, unless CHD was present.

RESULTS

Overall, 45 patients had cardiac transplantation for end-stage CHD (mean age, 26.1±18.4 years; range, 1 month to 65 years). Two patients (4%) had combined heart/liver transplantation; 1 (2%) had heart/kidney transplantation. Six patients (13%) had no previous cardiac operation; the remaining 39 patients had a mean of 3 (range, 1-8) previous cardiac operations. Patient survival (95% CI) at 1, 5, and 10 years was 89% (80%-98%), 89% (80%-98%), and 72% (56%-87%), respectively, while graft survival at 1, 5, and 10 years was 89% (80%-98%), 89% (80%-98%), and 61% (44%-78%), respectively. During the same era, the International Society for Heart & Lung Transplantation reported that survival in patients undergoing transplant for non-congenital diagnoses was 85%, 72%, and 56%, respectively. Over a mean follow-up of 8.7±6.2 years, rejection requiring treatment was documented in 35 patients (78%). Eleven patients (24%) have been diagnosed with neoplasia (8 skin, 1 blood, 1 lymph, and 1 other), and 3 patients (7%) have required retransplantation. Four patients (9%) have developed significant coronary vasculopathy; 1 successfully underwent retransplantation, and 3 died 6, 8, and 14 years after transplantation.

CONCLUSION

With appropriate patient selection and posttransplant monitoring, survival has improved for patients with complex end-stage CHD. Multiorgan transplantation is an option for selected patients with CHD.

Для цитирования: Robinson Jeffrey A, Driscoll David J, O'Leary Patrick W, Burkhart Harold M, Dearani Joseph A, Daly Richard C, Edwards Brooks S, Dahl Sonja H, Johnson Jonathan N. Cardiac and multiorgan transplantation for end-stage congenital heart disease.. Mayo Clinic proceedings. 2014. DOI: 10.1016/j.mayocp.2013.11.019.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.